Esperion Therapeutics Is Maintained at Buy by Needham
Express News | Esperion Therapeutics Inc : Needham Cuts Target Price to $6 From $8
Q2 2024 Esperion Therapeutics Inc Earnings Call
Earnings Call Summary | Esperion Therapeutics(ESPR.US) Q2 2024 Earnings Conference
Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript
Esperion Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Esperion Therapeutics Analyst Ratings
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
Esperion Therapeutics Shares Fall on Wider-Than-Expected 2Q Loss
Express News | Esperion Reiterates Its Full Year 2024 Operating Expense Guidance Of Approximately $225M-$245M, Including $20M In Non-cash Expenses Related To Stock Compensation
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q2 Loss $-0.33, Vs. Street Est of $-0.18
Express News | Esperion Therapeutics Q2 2024 GAAP EPS $(0.33) Misses $(0.18) Estimate, Sales $73.834M May Not Be Comparable To $49.056M Estimate
Express News | Esperion Therapeutics Inc: Reiterates Its Full Year 2024 Operating Expense Guidance
Express News | Esperion Therapeutics Q2 Operating Expenses USD 71.255 Million
Express News | Esperion Therapeutics Q2 Net Income USD -61.925 Million
Express News | Esperion Therapeutics Q2 Product Sales USD 28.302 Million
Express News | Esperion Therapeutics Q2 Basic EPS USD -0.33
Express News | Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
Express News | Esperion Therapeutics Q2 Operating Income USD 2.579 Million